Boston Scientific (NYSE:BSX) is looking double its emerging markets presence over the next 2 years as it seeks to catch up with larger competitors like Medtronic (NYSE:MDT), CEO Mike Mahoney told investors in San Francisco today.
Mahoney, speaking at the J.P. Morgan Healthcare Conference, said the company derived about 10% of its total sales from emerging markets in Brazil, Russia, India and China during the 3-months ended Sept. 30, 2014, an 18% increase from the same period in 2013.
Help employers find you! Check out all the jobs and post your resume.
Mahoney, speaking at the J.P. Morgan Healthcare Conference, said the company derived about 10% of its total sales from emerging markets in Brazil, Russia, India and China during the 3-months ended Sept. 30, 2014, an 18% increase from the same period in 2013.
Help employers find you! Check out all the jobs and post your resume.
